In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). (Q36467852)

14 August 2017

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). (English)

1 reference

14 August 2017

0 references

1 reference

Jensen PB

1

1 reference

14 August 2017

Vindeløv L

2

1 reference

14 August 2017

Roed H

3

1 reference

14 August 2017

Demant EJ

4

1 reference

14 August 2017

Sehested M

5

1 reference

14 August 2017

Skovsgaard T

6

1 reference

14 August 2017

Hansen HH

7

1 reference

14 August 2017

1 December 1989

1 reference

British Journal of Cancer

14 August 2017

language of work or name

English

0 references

published in

1 reference

14 August 2017

60

1 reference

14 August 2017

6

1 reference

14 August 2017

838-844

1 reference

describes a project that uses

14 August 2017

0 references

0 references

0 references

0 references

0 references

0 references

0 references

Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

A Detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Mechanism of multidrug resistance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Characterization of three new variant type cell lines derived from small cell carcinoma of the lung.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Establishment and identification of small cell lung cancer cell lines having classic and variant features.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Drug sensitivity of an adriamycin-resistant mutant subline of mouse lymphoblastoma L5178Y cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

New antitumor antibiotics, aclacinomycins A and B

21 September 2018

1 reference

12 December 2020

Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro

1 reference

12 December 2020

New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials

1 reference

12 December 2020

A phase I clinical trial of aclacinomycin A administered on a five-consecutive-day schedule

1 reference

12 December 2020

Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity

1 reference

12 December 2020

Long-term storage of samples for flow cytometric DNA analysis

1 reference

12 December 2020

Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial

1 reference

12 December 2020

Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1989.376

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

2574988

1 reference